Comparison of clinicopathological features and prognostic factors between advanced invasive lobular cancer and invasive ductal breast cancer / 肿瘤

ABSTRACT

Objective: To analyze and compare the clinicopathological features and prognostic factors between patients with advanced breast invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Methods: Fifty-nine female patients with advanced breast ILC from Tianjin Medical University Cancer Institute and Hospital were included in this retrospective case-controlled study. Matched two hundred and thirty-six female patients with advanced breast IDC were selected according to age at diagnosis and the time of surgery (±2 years) in Tianjin Medical University Cancer Institute and Hospital between January 2008 and December 2016. Clinical and pathological features and prognostic factors were analyzed by using univariate and multivariate analyses. Results: The clinical pathological features of clinical stage at initial diagnosis, T stage, M stage, histological degree, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor-2 (HER-2) status and molecular subtype were significantly different between two groups (all P < 0.05). The median ages at recurrence/metastasis of patients with breast ILC and IDC were 50 years (range 28-73) and 51 years (range 27-69), respectively. The differences in the number of first metastatic sites, lymph node metastasis, visceral metastasis, lung metastasis and bone metastasis were statistically significant between two groups (all P < 0.05). The median progression-free survivals of patients with breast ILC and IDC were 14 months (range 2-62) and 11 months (range 1-89), respectively (P = 0.121). The median metastasesoverall survivals (M-OS) of patients with ILC and IDC were 42 months (range 5-78) and 44 months ((range 1-110), respectively (P = 0.392). Multivariate analysis revealed that PR status, age at recurrence or metastasis and treatment of bone metastases were the independent predictors of survival in patients with advanced breast ILC (all P < 0.05). The molecular subtype, the number of first metastatic sites and pleural effusion were the independent prognostic factors in patients with breast IDC (all P < 0.05). Conclusion: Patients with advanced breast ILC have unique clinicopathological, recurrent/metastatic and prognostic features. It is necessary to reveal the definitive features of ILC and develop new personalized precision therapies.